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 Two recent publications from the New England Journal of Medicine 
(NEJM) [1;2] echoed in international and national news agencies (Agence 
France Presse [AFP]; Dallas news). The AFP journalist highlighted the 
importance of high triglycerides (TGs), but not low levels of high-density 
lipoprotein (HDL) cholesterol, as a risk factor for cardiovascular diseases 
(CVDs). Are HDL levels actually not relevant for CVDs in contrast to what the 
current guidelines are advocating [3]? Let us take a look at the data provided 
by the NEJM studies. In the first study [1], members of the Triglycerides and 
High-Density Lipoprotein (TG and HDL) Working Group sequenced the 
exome of 3734 persons and then tested the association of plasma TG with 
rare sequence variants. The gene most strongly associated with plasma TG 
encoded apolipoprotein C3 (ApoC3). Carriers of ApoC3 variants with lower 
TG levels displayed lower ApoC3 plasma levels and reduced risk of CVDs. 
Functionally, it makes sense that low ApoC3 levels favor increased TG levels 
because ApoC3 is an inhibitor of the lipoprotein lipase that participates in the 
catabolism of TGs [4]. As transfer of TG to HDLs accelerates their turn-over 
[4] reduced TG levels are also expected to positively affect HDL levels. 
Additionally, hydrolysis of TG-rich lipoproteins provides material for HDL 
synthesis. Via this effect, lower ApoC3 can also contribute to elevation in HDL 
levels [4]. It came therefore as no surprise that the NEJM study reported 
increased HDL levels in loss-of-function ApoC3 carriers. Such an association 
between loss-of-function of ApoC3 with reduced TG levels and increased HDL 
levels had in fact been described earlier in the Amish population [5] but the 
global impact of this mutation on CVD was not determined. 
The second NEJM study [2] applied a reverse approach. The authors initially 
demonstrated an association of TG levels and CVD risk and then determined 
that loss-of-function mutations in ApoC3, which they found associated with 
low TG levels, were also predictive for lower risks of CVD. In this case again, 
an inverse relationship was observed between TG and HDL levels. 
In conclusion, the two NEJM studies nicely demonstrated the impact of a TG-
modulating protein (ApoC3) on CVD risks but, as in most observational 
studies, cannot isolate the individual contributions of entangled biological 
parameters, such as TGs and HDLs, in the development of CVDs. In 
particular, the data reported in these studies cannot be used as evidence that 
TG levels causally determine CVD risks, as the authors in fact carefully 
pointed out (but not the journalist). 
Finally, in the context of HDLs and diabetes, recently reviewed in depth [3;4], 
a new observational study reports that low HDL levels predict earlier and 
greater intensity treatment with oral hypoglycemic agents and insulin in type 2 
diabetic individuals [6]. This work is in line with a large number of studies 
reporting that HDL levels predict incidence of type 2 diabetes development. Its 
novelty stems from the finding that in individuals with established diabetes, 
low HDL levels predict hastened deterioration of glucose control. Here again, 
causality cannot be inferred. As HDL and TG levels are so closely entangled, 
TGs may as well contribute to beta cell dysfunction in diabetic patients as 
reported in a recent retrospective study [7]. 
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Raising HDL levels is proposed to be a therapeutical approach in the context 
of CVDs and diabetes. This notion is based on the inverse relationship 
observed between HDL levels and risks of developing such diseases. The 
present study confirms the association between alcohol consumption and 
HDL levels. It also indicates that individual consuming alcohols are less likely 
to develop a metabolic syndrome. Considering alcohol, when moderately 
consumed, as therapeutic beneficial raises ethical and medical issues 
however. Nevertheless, it is certainly worthwhile to experimentally assess, at 
the molecular level, how alcohol exerts its beneficial effect as this may lead to 
the identification of molecules that could be targeted for the development of 
anti-atherogenic and anti-diabetogenic drugs. 
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The HDL components mediating their beneficial effects in pancreatic beta 
cells are not definitely characterized yet. ApoM, an apolipoprotein found in 
about 10% of HDLs, has the capacity to bind sphingosine-1-phosphate (S1P). 
This latter molecule is able to activate various signals in cells, including anti-
apoptotic pathways. The present study indicates that ApoM favors insulin 
secretion in a S1P receptor-dependent manner. It will be interesting in future 
studies to determine if ApoM-containing HDL particles are the only HDL 
particles that mediate beneficial effects in beta cells. 
 
